Better Health for All

Aldeyra Therapeutics is a biotechnology company entirely focused on developing novel therapies for immune-mediated diseases and unmet medical needs.

Its pipeline targets conditions such as retinitis pigmentosa (a rare genetic eye disease affecting over one million patients worldwide ), primary vitreoretinal lymphoma (a rare cancer with no FDA-approved therapies ), dry eye disease, allergic conjunctivitis, alcohol-associated hepatitis, metabolic inflammation, and dry age-related macular degeneration. The investigational product ADX-629 demonstrated statistically significant improvement in liver function in patients with mild to moderate alcohol-associated hepatitis , with improvements in MELD score (P=0.001 ), triglyceride levels (P<0.0001 ), and C-Reactive Protein (P<0.0001 ). Reproxalap has also shown positive trial outcomes for dry eye disease. The company does not generate revenue from products with negative health outcomes, and its entire research and development budget is dedicated to discovering and developing these health-improving therapies. In a Phase 2 clinical trial of ADX-629 involving four patients , no serious adverse events were reported, and no adverse events were deemed related to the drug. However, the FDA issued Complete Response Letters for reproxalap (twice ) and ADX-2191 , citing a need for additional efficacy data or lack of substantial evidence of effectiveness . The company has a compassionate use policy for investigational products.

Fair Money & Economic Opportunity

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing therapies, not a financial institution.

The company does not offer lending, deposit services, or other financial products to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fees, financial inclusion initiatives, customer financial data accessibility, fair lending compliance, wealth building outcomes, community finance reinvestment, financial literacy programs, debt burden ratios, geographic inclusion for financial services, or financial product simplicity, are not applicable to its operations.

Fair Pay & Worker Respect

In 2024, Aldeyra Therapeutics, Inc. had a workforce of 9 employees.

Its Chief Financial Officer was compensated as an independent contractor on an hourly contract through an external employer, meaning approximately 11.1% of the workforce is on an insecure contract. The company has no reported regulatory actions, violations, fines, or compliance issues related to labor laws or human rights. A potential minor compliance issue was noted regarding a Form 4 filing for a director, but this is not a labor-law violation. Due to the company's small workforce, specific metrics for living wage coverage, CEO to median pay ratio, voluntary employee turnover, and health insurance coverage are not applicable for meaningful assessment. No data is available on collective bargaining share, safety incident rate, pay equity ratios, or worker engagement scores.

Fair Trade & Ethical Sourcing

No information regarding Fair Trade & Ethical Sourcing, or any of the specific metrics (fair_trade_cert_share, audit_frequency, forced_child_labour_incidents, traceability_coverage, remediation_speed, ethical_clause_coverage, materials_risk_index, supplier_diversity_spend), is available in the provided articles for Aldeyra Therapeutics, Inc.

, , , ,

Honest & Fair Business

The company's consolidated financial statements are audited by an independent registered public accounting firm, BDO USA, P.C., since fiscal year 2013

, with the balance sheet data as of December 31, 2024, derived from these audited statements , implying approximately 100% coverage of the company's financial units. There have been no revisions to the company’s financial statements or changes to significant accounting policies in recent periods, including the nine months ended September 30, 2025 , and the fiscal year ended December 31, 2024 . No regulatory fines have been reported in the last three years , and the company is not currently a party to any material legal proceedings expected to have a material adverse effect . All directors, other than the Chief Executive Officer, are independent as defined by Nasdaq listing rules , indicating at least 80% conflict-free board members. The company has implemented whistleblower procedures with formal protocols , including an anonymous reporting system accessible via a toll-free phone number or the internet . It prohibits retaliation for good-faith reports of ethical violations , and concerns regarding accounting or auditing matters are promptly communicated to the audit committee , with the Ethics Manager providing quarterly reports summarizing all communications . An Anti-Corruption Manual has been adopted and is available on the company’s internal website , including additional restrictions and advance approval requirements for gifts to foreign government officials . However, training to ensure employee compliance with relevant laws is periodic and general , not specifically focused on anti-corruption, and lacks effectiveness metrics.

Kind to Animals

Aldeyra Therapeutics' Code of Ethics and Business Conduct, adopted in 2013

and amended in 2016, does not explicitly mention an animal testing policy, only stating that the company is subject to various laws and regulations regarding the experimental use of animals. The company extensively uses animal models for preclinical data across various compounds and conditions, including dry age-related macular degeneration, obesity, atopic dermatitis, inflammatory pain, alcoholic hepatitis, ocular inflammation, post-surgical healing, radiation mucositis, lung inflammation, ulcerative colitis, nephritis, and retinitis pigmentosa. , While "in vitro and animal studies" are mentioned for reproxalap, suggesting some non-animal methods are used, the detailed descriptions of animal models indicate that non-animal assays primarily cover early-stage screens and are rarely used for complex endpoints. In 2021, Aldeyra Therapeutics provided 60,000 € in funding for the "HSP-90 Inhibition in SARS-CoV-2 Infection" project at FU Berlin, which is related to alternative methods research.

No War, No Weapons

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated diseases. Its core business model means it has no involvement in arms manufacturing, military contracts, or conflict facilitation. The company explicitly states it has no significant involvement in military contracting, controversial weapons, or small arms.

Consequently, key performance indicators related to revenue from arms contracts, dual-use technology, sales to embargoed regimes, conflict divestment, military AI safeguards, conflict minerals, and conflict zone procurement are not applicable to its operations. The Board of Directors oversees the company's business. , and a Code of Ethics and Business Conduct, last amended April 25, 2016, outlines general legal and ethical conduct.

Planet-Friendly Business

Aldeyra Therapeutics, Inc. has not established Science-Based Targets (SBTi)

and has no formal climate commitments or initiatives . The company has not publicly committed to specific 2030 or 2050 climate goals . No environmental compliance violations were mentioned in the provided documents , , , , , , , , , , , .

Safe & Smart Tech

Users cannot directly access their personal information through the services and must contact the company to request deletion, correction, or updates.

The company states it is not aware of any cybersecurity threats that have materially affected its business. It complies with the California Online Privacy Protection Act and the Children’s Online Privacy Protection Act. Employees and contractors receive regular cybersecurity awareness training, including topics on social engineering and email fraud. The company engages IT managed service providers to monitor security threats and vulnerabilities and respond to incidents, and conducts cybersecurity penetration testing as warranted. Information collected from users upon registration or contact may include name, email address, mailing address, or phone number.